Drugs

, Volume 66, Issue 13, pp 1685–1700

Pharmacological Treatments for Thyroid Eye Disease

Authors

  • Sara P. Modjtahedi
    • Division of Orbital and Ophthalmic Plastic SurgeryJules Stein Eye Institute
    • Department of OphthalmologyJules Stein Eye Institute, David Geffen School of Medicine at University of California
  • Bobeck S. Modjtahedi
    • Division of Orbital and Ophthalmic Plastic SurgeryJules Stein Eye Institute
    • Department of OphthalmologyJules Stein Eye Institute, David Geffen School of Medicine at University of California
  • Ahmad M. Mansury
    • Division of Orbital and Ophthalmic Plastic SurgeryJules Stein Eye Institute
    • Department of OphthalmologyJules Stein Eye Institute, David Geffen School of Medicine at University of California
  • Dinesh Selva
    • Oculoplastic and Orbital Division, Department of Ophthalmology and Visual Sciences, Royal Adelaide HospitalUniversity of Adelaide
    • Department of OphthalmologyJules Stein Eye Institute, David Geffen School of Medicine at University of California
  • Raymond S. Douglas
    • Division of Orbital and Ophthalmic Plastic SurgeryJules Stein Eye Institute
    • Department of OphthalmologyJules Stein Eye Institute, David Geffen School of Medicine at University of California
  • Robert A. Goldberg
    • Division of Orbital and Ophthalmic Plastic SurgeryJules Stein Eye Institute
    • Department of OphthalmologyJules Stein Eye Institute, David Geffen School of Medicine at University of California
    • Division of Orbital and Ophthalmic Plastic SurgeryJules Stein Eye Institute
    • Department of OphthalmologyJules Stein Eye Institute, David Geffen School of Medicine at University of California
Therapy In Practice

DOI: 10.2165/00003495-200666130-00003

Cite this article as:
Modjtahedi, S.P., Modjtahedi, B.S., Mansury, A.M. et al. Drugs (2006) 66: 1685. doi:10.2165/00003495-200666130-00003

Abstract

Thyroid eye disease (TED), which affects the majority of patients with Grave’s disease, is associated with significant ophthalmic morbidity. In patients with mild disease, supportive treatment with lubricating medication can be sufficient. However, in patients with severe TED and disfiguring proptosis or sight-threatening neuropathy, more aggressive medical or surgical interventions are necessary. Corticosteroids remain the preferred pharmacological treatment modality in the majority of patients with an active inflammatory component. Other immunosuppressive drugs in combination with corticosteroids may be helpful in patients with corticosteroid-resistant TED. Newer agents such as somatostatin analogues have not shown to be of significant clinical benefit; however, initial studies on the use of antioxidants and cytokine antagonists are encouraging.

Copyright information

© Adis Data Information BV 2006